AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) Short Interest Update

AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) saw a large decrease in short interest in the month of May. As of May 15th, there was short interest totaling 137,078 shares, a decrease of 54.8% from the April 30th total of 303,165 shares. Based on an average daily volume of 1,558,811 shares, the short-interest ratio is presently 0.1 days. Currently, 0.9% of the company’s shares are sold short.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of AIM. DRW Securities LLC raised its stake in AIM ImmunoTech by 60.6% during the fourth quarter. DRW Securities LLC now owns 69,545 shares of the company’s stock worth $79,000 after acquiring an additional 26,254 shares in the last quarter. Sabby Management LLC acquired a new stake in AIM ImmunoTech during the 3rd quarter valued at approximately $79,000. Finally, Corient Private Wealth LLC acquired a new stake in AIM ImmunoTech during the 2nd quarter valued at approximately $87,000. Institutional investors and hedge funds own 12.02% of the company’s stock.

AIM ImmunoTech Trading Down 7.6%

AIM stock traded down $0.07 during midday trading on Tuesday, reaching $0.83. 25,085,300 shares of the company were exchanged, compared to its average volume of 74,279,088. The business has a 50-day moving average price of $0.51 and a two-hundred day moving average price of $0.95. AIM ImmunoTech has a one year low of $0.21 and a one year high of $20.35. The company has a current ratio of 1.01, a quick ratio of 1.01 and a debt-to-equity ratio of 0.10.

AIM ImmunoTech (NYSEAMERICAN:AIM) last announced its earnings results on Friday, May 15th. The company reported ($0.69) earnings per share (EPS) for the quarter. The firm had revenue of $0.02 million for the quarter. Research analysts anticipate that AIM ImmunoTech will post -1.47 earnings per share for the current year.

Analyst Ratings Changes

AIM has been the topic of a number of analyst reports. Zacks Research downgraded shares of AIM ImmunoTech from a “strong-buy” rating to a “hold” rating in a research report on Friday, February 6th. Ascendiant Capital Markets decreased their price target on shares of AIM ImmunoTech from $10.00 to $9.00 and set a “buy” rating for the company in a research note on Monday. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, AIM ImmunoTech has a consensus rating of “Buy” and a consensus price target of $9.00.

About AIM ImmunoTech

AIM ImmunoTech is a clinical-stage biotechnology company focused on the development and commercialization of immune-modulating therapies for the treatment of viral infections and cancer. The company’s lead product candidate, Ampligen (rintatolimod), is a proprietary toll-like receptor 3 (TLR3) agonist that aims to enhance the body’s innate immune response. AIM ImmunoTech’s research and development efforts center on demonstrating the safety and efficacy of Ampligen as both a standalone therapy and in combination with other treatments.

In addition to its oncology and antiviral programs, the company is advancing clinical trials of Ampligen in patients with chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) and exploring potential applications for emerging viral threats.